



Manuscripts

by SAKK and
Cooperative Groups
2023

Cancer	Type of trial	Title	Authors	Journal	Impact factor
Breast Cancers	IBCSG 24-02	Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT	Francis PA, Fleming GF, Láng I, Ciruelos EM, Bonnefoi HR, Bellet M, Bernardo A, Climent MA, Martino S, Bermejo B, Burstein HJ, Davidson NE, Geyer CE, Walley BA, Ingle JN, Coleman RE, Müller B, Le Du F, Loibl S, Winer E, Ruepp B, Loi S, Colleoni M, Coates AS, Gelber RD, Goldhirsch A, Regan MM	J CLIN ONCOL	45.3
	IBCSG 48-14 POSITIVE	Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer	Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim Jr HA, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Ruíz Borrego M, Moore HCF, Saunders C, Bjelic-Radusic V, Susnjar S, Cardoso F, Smith KL, Ferreiro T, Ribi K, Ruddy KJ, El-Abed S, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O	NEW ENGL J MED	176.079
	SAKK 22/10	Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial	Huober J, Weder P, Ribi K, Thürlimann B, Thery JC, Li Q, Vanlemmens L, Guiu S, Brain E, Grenier J, Dalenc F, Levy C, Savoye AM, Müller A, Membrez-Antonioli V, Gérard MA, Lemonnier J, Hawle H, Dietrich D, Boven E, Bonnefoi H	JAMA ONCOL	33.01
	SAKK 23/16	Association of Axillary Dissection With Systemic Therapy in Patients With Clinically Node-Positive Breast Cancer	Weber WP, Matrai Z, Hayoz S, Tausch C, Henke G, Zimmermann F, Montagna G, Fitzal F, Gnant M, Ruhstaller T, Muenst S, Mueller A, Lelièvre L, Heil J, Knauer M, Egle D, Sávolt Á, Heidinger M, Kurzeder C; TAXIS Study Writing Group; Zwahlen DR, Gruber G, Ackerknecht M, Kuemmel S, Bjelic-Radusic V, Smanyakó V, Vrieling C, Satler R, Hagen D, Becciolini C, Bucher S, Simonson C, Fehr PM, Gabriel N, Maráz R, Sarlos D, Dedes KJ, Leo C, Berclaz G, Fansa H, Hager C, Reisenberger K, Singer CF, Loibl S, Winkler J, Lam GT, Fehr MK, Kohlik M, Clerc K, Ostapenko V, Maggi N, Schulz A, Andreozzi M, Goldschmidt M, Saccilotto R, Markellou P.	JAMA SURG	16.681

Cancer	Type of trial	Title	Authors	Journal	Impact factor
Breast Cancers	SAKK 23/16	Impact of imaging-guided localization on performance of tailored axillary surgery in patients with clinically node-positive breast cancer: Prospective study within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)	Weber WP, Heidinger M, Hayoz S, Matrai Z, Tausch C, Henke G, Zwahlen DR, Gruber G, Zimmermann F, Montagna G, Andreozzi M, Goldschmidt M, Schulz A, Mueller A, Ackerknecht M, Tampaki EC, Bjelic-Radisic V, Kurzeder C, Sávolt Á, Smanyakó V, Hagen D, Müller DJ, Gnant M, Loibl S, Fitzal F, Markellou P, Bekes I, Egle D, Heil J, Knauer M	ANN SURG ONCOL	5.344
	SAKK 23/16	Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: Prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)	Tausch C, Däster K, Hayoz S, Matrai Z, Fitzal F, Henke G, Zwahlen DR, Gruber G, Zimmermann F, Andreozzi M, Goldschmidt M, Schulz A, Maggi N, Saccilotto R, Heidinger M, Mueller A, Tampaki EC, Bjelic-Radisic V, Sávolt Á, Smanyakó V, Hagen D, Müller DJ, Gnant M, Loibl S, Markellou P, Bekes I, Egle D, Ruhstaller T, Muenst S, Kuemmel S, Vrieling C, Satler R, Becciolini C, Bucher S, Kurzeder C, Simonson C, Fehr PM, Gabriel N, Maráz R, Sarlos D, Dedes KJ, Leo C, Berclaz G, Fansa H, Hager C, Reisenberger K, Singer CF, Montagna G, Reitsamer R, Winkler J, Lam GT, Fehr MK, Naydina T, Kohlik M, Clerc K, Ostapenko V, Lelièvre L, Heil J, Knauer M, Weber WP	BREAST CANCER RES TR	4.845
	SAKK 24/14	Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative, EGFR positive breast cancer A multicenter single arm phase II trial [SAKK 24/14]	Mamot C, Wicki A, Hasler-Strub U, Riniker S, Li Q, Holer L, Bärtschi D, Zaman K, von Moos R, Dedes KJ, Boos LA, Novak U, Bodmer A, Ritschard R, Obermann EC, Tzankov A, Ackermann C, Membréz-Antonioli V, Zürrer U, Caspar C, Deuster S, Senn M, Winterhalder R, Rochlitz C	SCI REP	4.996
Developmental Therapeutics	BASILEA CDI-CS-002	Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study	Joerger M, Hundsberger T, Haefliger S, von Moos R, Hottinger AF, Kaindle T, Engelhardt M, Marszewska M, Lane H, Roth P, Stathis A	INVEST NEW DRUGS	3.4
Gastrointestinal Cancers	DANTE	Perioperative atezolizumab in combination with FLOT chemotherapy vs. FLOT alone for resectable esophagogastric adenocarcinoma: results from the phase II portion of DANTE, a randomized, multicenter, phase II/III trial of the FLOT-AIO German Gastric Cancer Study Group and Swiss Group for Clinical Cancer Research SAKK	Lorenzen S, Götze TO, Thuss-Patience P, Biebl M, Homann N, Schenk M, Lindig U, Heuer V, Kretzschmar A, Goekkurt E, Haag GM, Riera-Knorrenschild J, Bolling C, Hofheinz RD, Zhan T, Angermeier S, Ettrich TJ, Siebenhuener AR, Elshafei M, Bechstein WO, Gaiser T, Loose M, Sookthai D, Kopp C, Pauligk C, Al-Batran SE	J CLIN ONCOL	45.3

Cancer	Type of trial	Title	Authors	Journal	Impact factor
Gastrointestinal Cancers	PROSPECT	Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048)	Basch E, Dueck AC, Mitchell SA, Mamon H, Weiser M, Saltz L, Gollub M, Rogak L, Ginos B, Mazza GL, Colgrove B, Chang G, Minasian L, Denicoff A, Thanarajasingam G, Musher B, George T, Venook A, Farma J, O'Reilly E, Meyerhardt JA, Shi Q, Schrag D	J CLIN ONCOL	45.3
	PROSPECT	Preoperative Treatment of Locally Advanced Rectal Cancer	Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, Goldberg J, Al Baghdadi T, Goodman KA, McWilliams RR, Farma JM, George TJ, Kennecke HF, Shergill A, Montemurro M, Nelson GD, Colgrove B, Gordon V, Venook AP, O'Reilly EM, Meyerhardt JA, Dueck AC, Basch E, Chang GJ, Mamon HJ	NEW ENGL J MED	176.079
	INOVATYON	INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.	Colombo N, Gadducci A, Sehouli J, Rulli E, Mäenpää J, Sessa C, Montes A, Ottevanger NB, Berger R, Vergote I, D'Incalci M, Churrua Galaz C, Chekerov R, Nyvang GB, Riniker S, Herbertson R, Fossati R, Barretina-Ginesta MP, Deryal M, Mirza MR, Biagioli E, Iglesias M, Funari G, Romeo M, Tasca G, Pardo B, Tognon G, Rubio-Pérez MJ, DeCensi A, De Giorgi U, Zola P, Benedetti Panici P, Aglietta M, Arcangeli V, Zamagni C, Bologna A, Westermann A, Heinzelmann-Schwarz V, Tsibulak I, Wimberger P, Poveda A	BR J CANCER	9.075
Leukemias	CLL13	First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia	Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber PB, Tadmor T, Lindström V, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Nösslinger T, Janssens A, Christiansen I, Baumann M, Frederiksen H, van der Klift M, Jäger U, Leys MBL, Hoogendoorn M, Lotfi K, Hebart H, Gaska T, Koene H, Enggaard L, Goede J, Regelink JC, Widmer A, Simon F, De Silva N, Fink AM, Bahlo J, Fischer K, Wendtner CM, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Levin MD, van Oers M, Geisler C, Stilgenbauer S, Hallek M	NEW ENGL J MED	176.079

Cancer	Type of trial	Title	Authors	Journal	Impact factor
Leukemias	CLL13	High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations	Fürstenau M, Thus YJ, Robrecht S, Mellink CHM, van der Kevie-Kersemaekers AM, Dubois J, von Tresckow J, Patz M, Gregor M, Thornton P, Staber PB, Tadmor T, Levin MD, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Janssens A, Christiansen I, Nösslinger T, Baumann M, Hebart H, Gaska T, Regelink JC, Dompeling EC, Lindström V, Juliusson G, Widmer A, Goede J, Goldschmidt N, Simon F, De Silva N, Fink AM, Fischer K, Wendtner CM, Ritgen M, Brüggemann M, Tausch E, Spaargaren M, Eldering E, Stilgenbauer S, Niemann CU, Hallek M, Eichhorst B, Kreuzer KA, Kater AP	BLOOD	10.452
	GRAALL 2003, GRAAL 2005, GRAAL 2014	Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study	Kim R, Bergugnat H, Pastoret C, Pasquier F, Raffoux E, Larcher L, Passet M, Gardel N, Delabesse E, Kubetzko S, Caye-Eude A, Meyer C, Marschalek R, Lafage-Pochitaloff M, Thiebaut-Bertrand A, Balsat M, Escoffre-Barbe M, Blum S, Baumann M, Banos A, Straetmans N, Gallego-Hernanz MP, Chalandon Y, Graux C, Soulier J, Leguay T, Hunault M, Huguet F, Lhéritier V, Dombret H, Boissel N, Clappier E	BLOOD	10.452
	GRAALL 2003, GRAALL 2005	Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL	Simonin M, Andrieu GP, Birsén R, Balsat M, Hypolite G, Courtois L, Graux C, Gardel N, Cayuela JM, Huguet F, Chalandon Y, Le Bris Y, Macintyre E, Gandemer V, Petit A, Rousselot P, Baruchel A, Bouscary D, Hermine O, Boissel N, Asnafi V	BLOOD	10.452
	GRAALL 2005	Impact of central nervous system involvement in adult patients with Philadelphia-negative acute lymphoblastic leukemia: a GRAALL-2005 study	Orvain C, Chantepie S, Thomas X, Escoffre-Barbe M, Huguet F, Desbrosses Y, Guillerm G, Uzunov M, Leguay T, Barbieux S, Vey N, Chevallier P, Malfuson JV, Lepretre S, Baumann M, Aykut M, Chaib A, Joris M, Zerazhi H, Stussi G, Chapiro J, Berthon C, Bonmati C, Jourdan E, Carp D, Marçais AR, Gallego-Hernanz MP, Vaida I, Bilger K, Villate A, Pasquier F, Chalandon Y, Maury S, Lheritier V, Ifrah N, Dombret H, Boissel N, Hunault-Berger M	HAEMATOLOGICA	11.04

Cancer	Type of trial	Title	Authors	Journal	Impact factor
Leukemias	GRAALL 2014	Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic TP53-Mutant Clonal Hematopoiesis	Kim R, Bergugnat H, Larcher L, Duchmann M, Pas-set M, Gachet S, Cuccuini W, Lafage-Pochitaloff M, Pastoret C, Gardel N, Asnafi V, Schafer BW, Delabesse E, Itzykson R, Ades L, Hicheri Y, Chalandon Y, Graux C, Chevallier P, Hunault M, Leguay T, Huguet F, Lheritier V, Dombret H, Soulier J, Rousselot P, Boissel N, Clappier E	BLOOD CANCER DISCOV	
	HOVON 132	Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival	Tettero JM, Ngai LL, Bachas C, Breems DA, Fischer T, Gjertsen BT, Gradowska P, Griskevicius L, Janssen JJWM, Juliusson G, Maertens J, Manz MG, Pabst T, Passweg J, Porkka K, Valk PJM, Löwenberg B, Ossenkoppele GJ, Cloos J	HAEMATOLOGICA	11.047
	HOVON 135	Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine	Hilberink JR, van Zeventer IA, Chitu DA, Pabst T, Klein SK, Stussi G, Griskevicius L, Valk PJM, Cloos J, van de Loosdrecht AA, Breems D, van Lammeren-Venema D, Boersma R, Jongen-Lavrencic M, Fehr M, Hoogendoorn M, Manz MG, Söhne M, van Marwijk Kooy R, Deeren D, van der Poel MWM, Legdeur MC, Tick L, Chalandon Y, Ammatuna E, Blum S, Löwenberg B, Ossenkoppele GJ; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); Swiss Group for Clinical Cancer Research (SAKK); Huls G.	BLOOD CANCER J	8.125
Lung Cancers		Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced Non-Small Cell Lung Cancer (NSCLC): A Swiss cohort study	Schuler A, Huser J, Schmid S, Schär S, Scherz A, Gautschi O, Mauti L, von Briel T, Waibel C, Wannesson L, Pankovics J, Mark MT, Rothschild SI, Addeo A, Janthur WD, Siano M, Boos L, Britschgi C, Früh M	LUNG CANCER	5.3
	SAKK 16/14	Evaluation of radiological response, pathological response and relapse-free survival as the surrogate endpoints for overall survival in the neoadjuvant immunotherapy trials: meta-analyses of individual patient data	Nie R, Chen F, Provencio M, Wang Y, van den Ende T, van Laarhoven HWM, Yuan S, Pless M, Hayoz S, Zhou Z, Li Y, Rothschild SI, Cai M	EUR J CANCER	10.002
	SAKK 16/96, 16/00, 16/01, 16/08	Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small cell lung cancer. Retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01 and 16/14	König D, Savic Prince S, Hayoz S, Zens P, Berezowska S, Jochum W, Stauffer E, Braunersreuther V, Trachsel B, Thierstein S, Mark M, Schmid S, Curioni-Fontecedro A, Addeo A, Opitz I, Guckenberger M, Früh M, Betticher DC, Ris HB, Stupp R, Rothschild SI, Bubendorf L, Pless M	ESMO OPEN	7.3

Cancer	Type of trial	Title	Authors	Journal	Impact factor
Lymphomas	HD 16	Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma	Fuchs M, Jacob AS, Kaul H, Kobe C, Kuhnert G, Pabst T, Greil R, Bröckelmann PJ, Topp MS, Just M, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Dührsen U, Meissner J, Viardot A, Eich HT, Baues C, Diehl V, Rosenwald A, Buehnen I, von Tresckow B, Dietlein M, Borchmann P, Engert A, Eichenauer DA	LEUKEMIA	10.431
	HD 18	Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced stage Hodgkin Lymphoma: results from the randomized international GHSG HD18 trial	Ferdinandus J, Müller H, Damaschin C, Jacob AS, Meissner J, Krasniqi F, Mey U, Schöndube D, Thiemer J, Mathas S, Zijlstra J, Greil R, Feuring-Buske M, Markova J, Ruffer JU, Kobe C, Eich HT, Baues C, Fuchs M, Borchmann P, Behringer K	ANN ONCOL	50.5
	HD16, HD17	Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies	Eichenauer DA, Bühnen I, Baues C, Kobe C, Kaul H, Greil R, Moccia A, Zijlstra JM, Hertenstein B, Topp MS, Just M, von Tresckow B, Eich HT, Fuchs M, Dietlein M, Hartmann S, Engert A, Borchmann P	BLOOD	10.452
	HOVON 127/ SAKK 37/16	R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial	Chamuleau MED, Stenner F, Chitu DA, Novak U, Minnema MC, Geerts P, Stevens WBC, Zenz T, van Imhoff GW, Wu KL, Demandt AMP, Kersten MJ, Terpstra WE, Tick LW, Deeren D, Van Den Neste E, Gregor M, Veelken H, Böhmer LH, Caspar CB, Mutsaers P, Refos JM, Sewsaran R, Fu L, Seefat RL, Uyl-de Groot CA, Dirnhofer S, Van Den Brand M, de Jong D, Nijland M, Lugtenburg P	LANCET HAEMATOL	24.7
	REMoDL-B	Differential efficacy from the addition of bortezomib to R-CHOP in diffuse large B-cell lymphoma according to molecular subgroup in the REMoDL-B study with 5 years follow up	Davies AJ, Barrans S, Stanton L, Caddy J, Wilding S, Saunders G, Mamot C, Novak U, McMillan A, Fields P, Collins GP, Stephens R, Cucco F, Sha C, van Hoppe M, Tooze R, Davies JR, Griffiths G, Schuh A, Burton C, Westhead DR, Du MQ, Johnson PWM	J CLIN ONCOL	45.3
	SAKK 36/13	Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)	Novak U, Fehr M, Schär S, Dreyling M, Schmidt C, Derenzini E, Zander T, Hess G, Mey U, Ferrero S, Mach N, Boccomini C, Böttcher S, Voegeli M, Cairoli A, Ivanova VS, Menter T, Dirnhofer S, Scheibe B, Gadiant S, Eckhardt K, Zucca E, Driessen C, Renner C	eClinicalMedicine	15.1
	SAKK 38/07	Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma	Eertink JJ, Zwezerijnen GJC, Heymans MW, Pieplbosch S, Wiegers SE, Dührsen U, Hüttmann A, Kurch L, Hanoun C, Lugtenburg PJ, Barrington SF, Mikhaeel NG, Ceriani L, Zucca E, Czibor S, Györke T, Chamuleau MED, Hoekstra OS, de Vet HCW, Boellaard R, Zijlstra JM	BLOOD	10.452

Cancer	Type of trial	Title	Authors	Journal	Impact factor
Lymphomas	SAKK 39/16	Alternate-day dosing of pomalidomide in relapsed/refractory multiple myeloma: a multicenter, single-arm phase 2 trial	Zander T, Pabst T, Schär S, Aebi S, Mey U, Novak U, Lerch E, Rhyner Agocs G, Goede J, Maniecka Z, Hayoz S, Rüfer A, Renner C, Driessen C	LEUKEMIA	12.883
Sarcomas	GISG 11, PazoQoL	Electronic Patient Reported Outcome (ePRO) Measures in Patients with Soft Tissue Sarcoma (STS) Receiving Palliative 3 Treatment	Hofer, S., Hentschel, L., Richter, S., Blum, V., Kramer, M., Kasper, B., Riese, C., Schuler, M.K	CANCERS	6.639
	SAKK 57/16	SAKK 57/16 Nab-Paclitaxel And Gemcitabine in soft tissue sarcoma (NAPAGE): Final results from the phase Ib/II trial with >2y median follow up	Digklla A, Kollár A, Dietrich D, Kronig MN, Britschgi C, Rordorf T, Joerger M, F. Krasniqi F, Metaxas Y, Colombo I, Ribi K, Rothermundt C	EUR J CANCER	5.417
Urogenital Cancers	SAKK 06/17	Perioperative chemo-immunotherapy with Durvalumab for muscle-invasive urothelial carcinoma: primary analysis of the single arm phase II trial SAKK 06/17	Cathomas R, Rothschild SI, Hayoz S, Bubendorf L, Özdemir BC, Kiss B, Erdmann A, Aeppli S, Mach N, Strebel RT, Hadaschik B, Berthold D, John H, Zihler D, Schmid M, Alborelli I, Schneider M, Musilova J, Spahn M, Petrausch U	J CLIN ONCOL	45.3
	SAKK 06/19	Intravesical recombinant BCG followed by perioperative chemo-immunotherapy for patients with muscle-invasive bladder cancer (MIBC). A multicenter, single arm phase 2 trial (SAKK 06/19)	Petrausch U, Spahn M, Schneider M, Hayoz S, Rentsch CA, Rothschild S, Omlin A, Cathomas R	BMJ OPEN	3.007
	SAKK 08/16	Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)	Gillessen S, Procopio G, Hayoz S, Kremer E, Schwitler M, Caffo O, Lorente D, Pedrazzini A, Roubaud G, Nenan S, Omlin A, Buttigliero C, Delgado Mingorance JI, González-Del-Alba A, Delgado MT, Nole F, Turco F, Pereira Mestre R, Ribi K, Cathomas R	J CLIN ONCOL	45.3
	STAMPEDE	Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol	Attard G, Murphy L, Clarke NW, Sachdeva A, Jones C, Hoyle A, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Gilson C, Rush H, Abdel-Aty H, Amos CL, Murphy C, Chowdhury S, Malik Z, Russell JM, Parkar N, Pugh C, Diaz-Montana C, Pezaro C, Grant W, Saxby H, Pedley I, O'Sullivan JM, Birtle A, Gale J, Srihari N, Thomas C, Tanguay J, Wagstaff J, Das P, Gray E, Alzouebi M, Parikh O, Robinson A, Montazeri AH, Wylie J, Zarkar A, Cathomas R, Brown MD, Jain Y, Dearnaley DP, Mason MD, Gilbert D, Langley RE, Millman R, Matheson D, Sydes MR, Brown LC, Parmar MKB, James ND; STAMPEDE investigators	LANCET ONCOL	54.433

Cancer	Type of trial	Title	Authors	Journal	Impact factor
Methodology		Completion and publication of clinical trials in a cooperative group: a cohort study of trials of the Swiss Group for Clinical Cancer Research (SAKK)	Hayoz S, Kasenda B, Schenker AL, Kopp C, Schär S, Thürlimann B, von Moos R, Pless M	BMJ OPEN	3.007
SAKK Services		A long-term retrospective observational study at a medium-sized medical oncology service in Switzerland: comparison of overall survival with a national cohort and adherence to treatment guidelines	Gross-Erne M, Zimmerli L, Bassetti S, Li Q, Feller A, Mingrone W	SWISS MED WKLY	
		The role of immune checkpoint inhibitors in clinical practice: an analysis of the treatment patterns, survival and toxicity rates by sex	Wahli MN, Hayoz S, Hoch D, Ryser CO, Hoffmann M, Scherz A, Schwacha-Eipper B, Häfliger S, Wampfler J, Berger MD, Novak U, Özdemir BC	J CANCER RES CLIN ONCOL	4.322
		Prognostic relevance of mixed histological subtypes in invasive breast carcinoma: a retrospective analysis	Rechsteiner A, Dietrich D, Varga Z	J CANCER RES CLIN ONCOL	4.322
		Prescription patterns, recurrence and toxicity rates of adjuvant treatment for stage III/IV melanoma- A real world single-centre analysis	Hoffmann M, Hayoz S, Özdemir B C	BIOLOGY	5.007
		Prediction of Biochemical Recurrence Based on Molecular Detection of Lymph Node Metastasis After Radical Prostatectomy	Oezdemir BC, Arnold N, Fleischmann A, Hensel J, Klima I, Kruihof-de Julio M, Burkhard F, Hayoz S, Kiss B, Thalmann GM	EUR UROL OPEN SCI	3.000